332 related articles for article (PubMed ID: 9590413)
1. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
Cloud ML; Enas N; Humphries TJ; Bassion S
Dig Dis Sci; 1998 May; 43(5):993-1000. PubMed ID: 9590413
[TBL] [Abstract][Full Text] [Related]
2. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry HD; Markham A
Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of rabeprazole once daily for acid-related disorders.
Lanza F; Bardhan KD; Perdomo C; Niecestro R; Barth J
Dig Dis Sci; 2001 Mar; 46(3):587-96. PubMed ID: 11318537
[TBL] [Abstract][Full Text] [Related]
4. Rabeprazole: an update of its use in acid-related disorders.
Carswell CI; Goa KL
Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
[TBL] [Abstract][Full Text] [Related]
5. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Stack WA; Knifton A; Thirlwell D; Cockayne A; Jenkins D; Hawkey CJ; Atherton JC
Am J Gastroenterol; 1998 Oct; 93(10):1909-13. PubMed ID: 9772054
[TBL] [Abstract][Full Text] [Related]
7. [Comparative study of proton pump inhibitors].
Herszényi L; Tulassay Z
Orv Hetil; 2001 Sep; 142(36):1953-61. PubMed ID: 11680100
[TBL] [Abstract][Full Text] [Related]
8. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Caos A; Breiter J; Perdomo C; Barth J
Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of efficacy, safety and tolerability rabeprazole in treatment of acid-peptic diseases ].
de Freitas JA; Lima LM; Ranieri JL; Olivieri JC; Fragoso HJ; Chinzon D
Arq Gastroenterol; 2002; 39(1):60-5. PubMed ID: 12184168
[TBL] [Abstract][Full Text] [Related]
10. Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans.
Celinski K; Konturek PC; Konturek SJ; Slomka M; Cichoz-Lach H; Brzozowski T; Bielanski W
J Physiol Pharmacol; 2011 Oct; 62(5):521-6. PubMed ID: 22204799
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
Thjodleifsson B; Rindi G; Fiocca R; Humphries TJ; Morocutti A; Miller N; Bardhan KD;
Aliment Pharmacol Ther; 2003 Feb; 17(3):343-51. PubMed ID: 12562446
[TBL] [Abstract][Full Text] [Related]
12. [Proton-pump inhibitor Rabeprazole: faster acid- and symptom-control].
Dtsch Med Wochenschr; 1998 Nov; 123(47 Suppl):1-4. PubMed ID: 9856116
[No Abstract] [Full Text] [Related]
13. [Pharma-clinics medication of the month. Rabeprazole (Pariet)].
Louis E
Rev Med Liege; 2002 Jan; 57(1):53-6. PubMed ID: 11899500
[TBL] [Abstract][Full Text] [Related]
14. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
15. The benefit/risk profile of rabeprazole, a new proton-pump inhibitor.
Johnson D; Perdomo C; Barth J; Jokubaitis L
Eur J Gastroenterol Hepatol; 2000 Jul; 12(7):799-806. PubMed ID: 10929909
[TBL] [Abstract][Full Text] [Related]
16. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
Caos A; Moskovitz M; Dayal Y; Perdomo C; Niecestro R; Barth J
Am J Gastroenterol; 2000 Nov; 95(11):3081-8. PubMed ID: 11095321
[TBL] [Abstract][Full Text] [Related]
17. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.
Wang HH; Chou JW; Liao KF; Lin ZY; Lai HC; Hsu CH; Chen CB
World J Gastroenterol; 2005 Mar; 11(11):1680-4. PubMed ID: 15786549
[TBL] [Abstract][Full Text] [Related]
18. [H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Bardou M
Rev Prat; 2001 Apr; 51(7):789-95. PubMed ID: 11387678
[No Abstract] [Full Text] [Related]
19. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Florent C
Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
[TBL] [Abstract][Full Text] [Related]
20. Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease.
Sloan S
Am J Gastroenterol; 2003 Mar; 98(3 Suppl):S49-55. PubMed ID: 12644031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
